Results 21 to 30 of about 115,969,812 (153)

Tripeptidyl peptidase I promotes human endometrial epithelial cell adhesive capacity implying a role in receptivity

open access: yesReproductive Biology and Endocrinology, 2020
The endometrium undergoes cyclic remodelling throughout the menstrual cycle in preparation for embryo implantation which occurs in a short window during the mid-secretory phase.
Leilani L. Santos   +2 more
doaj   +2 more sources

Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSC-derived retinal organoids and retina-on-chip

open access: yesCell Reports Medicine
Summary: Mutations in the tripeptidyl peptidase 1 (TPP1) gene lead to neuronal ceroid lipofuscinosis type 2 (CLN2), characterized by lysosomal accumulation of lipofuscins predominantly in the brain and retina.
Serena Corti   +24 more
doaj   +2 more sources

Two-year follow-up of gait and postural control following initiation of recombinant human tripeptidyl intracerebroventricular enzyme replacement therapy in two atypical CLN2 patients

open access: yesScientific Reports
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder leading to premature mortality. Ambulatory CLN2 patients typically receive standard of care treatment through biweekly intracerebroventricular (ICV) enzyme ...
Rahul Soangra   +3 more
doaj   +2 more sources

Systematic discovery of disease-modifying targets by prediction from knowledge graph-based AI model and experimental validation: Parkinson’s disease case

open access: yesComputational and Structural Biotechnology Journal
The development of disease-modifying therapies (DMTs) for Parkinson’s disease (PD) remains a critical unmet need. Despite extensive research efforts, no therapy capable of slowing or halting PD progression has been approved.
Minyoung So   +7 more
doaj   +2 more sources

Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres

open access: yesERJ Open Research, 2021
There is an unmet need for novel biomarkers in the diagnosis of multifactorial COPD. We applied next-generation proteomics to serum extracellular vesicles (EVs) to discover novel COPD biomarkers.
Taro Koba   +32 more
doaj   +1 more source

Neuronal Ceroid Lipofuscinosis Type 2: A Case Series from Argentina

open access: yesJournal of Inborn Errors of Metabolism and Screening, 2022
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare autosomal recessive neurodegenerative disorder caused by mutations in the CLN2/TPP1 gene, leading to a deficiency in tripeptidyl peptidase 1 activity.
Guillermo Guelbert, Norberto Guelbert
doaj   +1 more source

The LINCE Project: A Pathway for Diagnosing NCL2 Disease

open access: yesFrontiers in Pediatrics, 2022
IntroductionNeuronal Ceroid Lipofuscinosis (NCL) comprises a clinically and genetically heterogeneous group of 13 neurodegenerative lysosomal storage disorders.
Daniel Rodrigues   +10 more
doaj   +1 more source

Astaxanthin Alleviates Foam Cell Formation and Promotes Cholesterol Efflux in Ox-LDL-Induced RAW264.7 Cells via CircTPP2/miR-3073b-5p/ABCA1 Pathway

open access: yesMolecules, 2023
Atherosclerosis (AS) is a common cardiovascular disease and remains the leading cause of death in the world. It is generally believed that the deposition of foam cells in the arterial wall is the main cause of AS.
Zhexiao Zhang   +7 more
doaj   +1 more source

Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression

open access: yesJournal of Neuroinflammation, 2021
Background Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes.
Miriam S. Domowicz   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy